Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 136

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1A
Chunk 136
---
 in the future prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business. 

In addition, certain of our future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, we may in the future enter into license agreements that are not assignable or transferable, or that require the licensor’s express consent in order for an assignment or transfer to take place. 

 81

Risks Related to Ownership of Our Common Stock 

The price of our stock may be volatile, and you could lose all or part of your investment. 

The trading price of our common stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this “Risk Factors” section and elsewhere in this Annual Report on Form 10-K, these factors include: 

•the results of our ongoing, planned or any future preclinical studies, clinical trials or clinical development programs; 

•the commencement, enrollment, or results of clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates; 

•adverse results or delays in preclinical studies and clinical trials; 

•our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial, including due to the suspension of a clinical trial by the FDA or other regulatory authorities; 

•any delay in our regulatory filings or any adverse regulatory decisions, including failure to receive regulatory approval of our product candidates; 

•changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals; 

•adverse developments concerning our manufacturers or our manufacturing plans; 

•our inability to obtain adequate product supply for any licensed product or inability to do so at acceptable prices; 

•our inability to establish collaborations if needed; 

•our failure to commercialize our product candidates; 

•additions or departures of key scientific or management personnel; 

•unanticipated serious safety concerns related to the use of our product candidates; 

•introduction of new products or services offered by us or our competitors; 

•announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or